CHRISTIE BALLANTYNE to Proprotein Convertase 9
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Proprotein Convertase 9.
Connection Strength
3.187
-
PCSK9-targeted therapies: present and future approaches. Nat Rev Cardiol. 2021 12; 18(12):805-806.
Score: 0.703
-
Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. Nat Rev Cardiol. 2017 07; 14(7):385-386.
Score: 0.513
-
Oral PCSK9 Inhibitors. Curr Atheroscler Rep. 2024 05; 26(5):147-152.
Score: 0.206
-
Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of?siRNA Therapies for Prevention? J Am Coll Cardiol. 2023 12 12; 82(24):2262-2264.
Score: 0.202
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
Score: 0.195
-
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 04 25; 81(16):1553-1564.
Score: 0.192
-
Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis. 2022 05; 349:110-122.
Score: 0.181
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
Score: 0.144
-
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016 Jun; 176:83-92.
Score: 0.118
-
The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia. Curr Atheroscler Rep. 2015 May; 17(5):508.
Score: 0.111
-
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015 May 01; 115(9):1212-21.
Score: 0.110
-
Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014 Oct; 11(10):563-75.
Score: 0.105
-
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J. 2013 Jun; 34(24):1783-9.
Score: 0.096
-
Clinical use of genetic typing in human lipid disorders. J Clin Lipidol. 2012 May-Jun; 6(3):199-207.
Score: 0.089
-
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vasc Health Risk Manag. 2022; 18:555-566.
Score: 0.046
-
Clinical Genetic Testing for Familial?Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018 08 07; 72(6):662-680.
Score: 0.035
-
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. Clin Cardiol. 2016 Mar; 39(3):137-44.
Score: 0.030
-
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 08; 370(19):1809-19.
Score: 0.026
-
Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014 Feb 06; 94(2):233-45.
Score: 0.026
-
Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet. 2013 Mar; 9(3):e1003379.
Score: 0.024
-
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 May-Jun; 5(3):133-140.
Score: 0.021
-
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005 May 17; 45(10):1611-9.
Score: 0.014